MAR-24-2005 11:23 NOVARTIS INTELL FORM PTO-1595 RE 09-15-20	973 781 8064 P. 03
(Rev. 6-93) OMB No. 0651-0011 (exp. 4/94)	
To the Honorable Commissioner of	48 record the attached original documents or copy thereof.
Name of conveying party(ies):	2. Name and address of receiving party(ies)
Gurdip Bhalay, Stephen Paul Collingwood,	Name: Novertis AG
Robin Alec Fairhurst, Sylvie Felicite Gomez,	
Reto Naef, David Andrew Sandham	
Additional name(s) of conveying party(ies) attached? Yes No	
Nature of conveyance:	^-
	Street Address: <u>Lichtstrasse 35</u>
Security Agreement Change of Name	
Other	City: BaselState: Switzerland ZIP: 4056
Execution Date: <u>9/19/02; 9/19/02; 9/20/02; 9/18/02;</u>	Additional name(s) & address(es) attached? Yes No
9/18/02; 9/19/02	
Application number(s) or patent number(s):	C3 -10
If this document is being filed together with a new application	n, the execution date of the application is:
A. Patent Application No.(s)	B. Patent No.(s)
10/644,328	항원 호텔
Additional numbers atta	ched? 🗆 Yes 🖾 No
Name and address of party to whom correspondence concerning document should be mailed:	1 de la companya de l
Name:Novartis	7. Total fee (37 CFR 3.41) \$
Internal Address: Corporate Intellectual Property	☐ Enclosed
Internal Address. Corporate Internation	Authorized to be charged to deposit account and any other additional fees required.
Street Address: One Health Plaza, Building 430	8. Deposit account number:
City: East Hanover_State: NJ_ZIP: 07936-1080_	19-0134 (in the name of Novartis)
· —	(Attach duplicate copy of this page if paying by deposit account)
DO NOT L	ISE THIS SPACE
Copy of the original document. Gregory C. Houghton Name of Person Signing	Signature of Express Mall below
Total number of pages including co	ver sheet, attachments, and document: 5
Director of the US Paten	i with required cover sheet information to: t an Trademark 伊内内的伊格克斯斯巴克斯 MAIL iria, VA 22313-146NDER 37 CFR 1.10

09/14/2004 MGETACHE 00000055 190134 10644328

01 FC:8021

40.00 DA

Express Mail Label Number

700164765

us (PCT) Case 4-31388A/HO 27

ASSIGNMENT

I / We Gurdip Bhalay
Stephen Paul Collingwood
Robin Alec Fairhurst
Sylvie Felicite Gomez
Reto Naef
David Andrew Sandham

for good and valuable consideration, the receipt and 'adequacy of which is hereby acknowledged, do hereby sell and assign to *Novartis AG*, a *Company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland*, its successors, assigns and legal representatives all my/our right, title and interest, in and for the United States of America, in and to the invention entitled:

8-QUINOLINXANTHINE AND 8-ISOQUINOLINXANTHINE DERIVATIVES AS PDE 5 INHIBITORS

invented by me/us and described in the international application

No. PCT/EP01/03909

filed April 5, 2001

and all United States Letters Patent which may be granted therefor, and all divisions, reissues, continuations and extensions thereof, the said interest being the entire ownership of the said Letters Patent when granted, to be held and enjoyed by the said *Novartis AG*, its successors, assigns or other legal representatives, to the full end of the term for which said Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this assignment and sale had not been made;

And I/we hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to the said **Novartis AG**.

	Signed on
Gudinto alas	19-09-02.
Stephen Paul Collingwood	1a-09-2002.
Stephen Paul Collingwood	
Robin Alec tawhent	20-09-02
Robin Alec Fairhurst	,
Sylvie Felicite Gomes	18 Septembre 2002

PATENT US 07/01

REEL: 015957 FRAME: 0237

MAR-24-2005 11:24

Reto Naef

Devel Julian Sullan

19-09-2002

David Andrew Sandhan

US 07/01

PATENT REEL: 015957 FRAME: 0238 us (PCT) Case 4-31388A/HO 27

<u>ASSIGNMENT</u>

I / We Gurdip Bhalay
Stephen Paul Collingwood
Robin Alec Fairhurst
Sylvie Fellcite Gomez
Reto Naef
David Andrew Sandham

for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign to *Novartis AG, a Company organized under* the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland, its successors, assigns and legal representatives all my/our right, title and interest, in and for the United States of America, in and to the invention entitled:

8-QUINOLINXANTHINE AND 8-ISOQUINOLINXANTHINE DERIVATIVES AS PDE 5 INHIBITORS

invented by me/us and described in the international application

No. PCT/EP01/03909

filed April 5, 2001

and all United States Letters Patent which may be granted therefor, and all divisions, reissues, continuations and extensions thereof, the said interest being the entire ownership of the said Letters Patent when granted, to be held and enjoyed by the said *Novartis AG*, its successors, assigns or other legal representatives, to the full end of the term for which said Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this assignment and sale had not been made;

And I/we hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to the said *Novartis AG*.

<u></u>	<u> </u>		
Gurdip Bhalay			
Stephen Paul Collingwood			
Robin Alec Fairhurst			
Sylvie Felicite Gomez			

US 07/01

973 781 8064

P 07

Reto Naef

18/09/ 2002

David Andrew Sandham

US 07/01

PATENT REEL: 015957 FRAME;;; 0240 € 17 PRAME; 10 PRAME;